Xu-Juan Xu1, Hai-Yan Huang, Hong-Lin Chen. 1. Department of Nursing, Affiliated Hospital of Nantong University, Xi Si Road 20#, Nantong, Jiangsu Province, 226001, People's Republic of China, pphss@126.com.
Abstract
UNLABELLED: We performed a meta-analysis to study the association between erythropoietin (EPO) and the development of retinopathy of prematurity (ROP) in preterm newborn infants. Studies were identified through PubMed (1966-) and ISI databases (1965-) literature searches. Results and effect sizes are expressed as odds ratio (OR) with 95 % confidence intervals (CI). Fourteen studies identified to the meta-analysis, including 3,484 preterm newborn infants. A total of 563 of 1,221 babies treated with EPO had ROP (46.1 %) vs. 420 of 1,134 babies without EPO (37.0 %). No significant difference was found in the ROP risk between the two groups, with the OR 1.592 (95 % CI 0.901-2.812). A total of 192 of 1,298 babies treated with EPO had severe ROP (stage 3-4) (14.8 %) vs. 166 of 1,199 babies without EPO (13.8 %). The OR was 1.203 (95 % CI 0.763-1.896). No significant publication bias was found. Sensitivity analyses showed the results were robust. CONCLUSION: Our meta-analysis indicates that EPO treatment is not associated with the development of ROP in preterm infants. But this conclusion should be confirmed by further high-quality researches.
UNLABELLED: We performed a meta-analysis to study the association between erythropoietin (EPO) and the development of retinopathy of prematurity (ROP) in preterm newborn infants. Studies were identified through PubMed (1966-) and ISI databases (1965-) literature searches. Results and effect sizes are expressed as odds ratio (OR) with 95 % confidence intervals (CI). Fourteen studies identified to the meta-analysis, including 3,484 preterm newborn infants. A total of 563 of 1,221 babies treated with EPO had ROP (46.1 %) vs. 420 of 1,134 babies without EPO (37.0 %). No significant difference was found in the ROP risk between the two groups, with the OR 1.592 (95 % CI 0.901-2.812). A total of 192 of 1,298 babies treated with EPO had severe ROP (stage 3-4) (14.8 %) vs. 166 of 1,199 babies without EPO (13.8 %). The OR was 1.203 (95 % CI 0.763-1.896). No significant publication bias was found. Sensitivity analyses showed the results were robust. CONCLUSION: Our meta-analysis indicates that EPO treatment is not associated with the development of ROP in preterm infants. But this conclusion should be confirmed by further high-quality researches.
Authors: Nishant Shah; Pushkaraj Jadav; Dominique Jean-Baptiste; Jay Weedon; Lourdes M Cohen; M Roger Kim Journal: Am J Perinatol Date: 2009-06-29 Impact factor: 1.862
Authors: H Donato; N Vain; P Rendo; N Vivas; L Prudent; M Larguía; J Digregorio; C Vecchiarelli; R Valverde; C García; P Subotovsky; C Solana; A Gorenstein Journal: Pediatrics Date: 2000-05 Impact factor: 7.124
Authors: J Figueras-Aloy; E Alvarez-Domínguez; M Morales-Ballus; M D Salvia-Roiges; G Moretones-Suñol Journal: An Pediatr (Barc) Date: 2010-10-15 Impact factor: 1.500
Authors: Kevin K Suk; Jennifer A Dunbar; Anthony Liu; Noha S Daher; Cheri K Leng; Jason K Leng; Pauline Lim; Samantha Weller; Elba Fayard Journal: J AAPOS Date: 2008-06 Impact factor: 1.220
Authors: K M Shannon; J F Keith; W C Mentzer; R A Ehrenkranz; M S Brown; J A Widness; C A Gleason; E M Bifano; D D Millard; C B Davis Journal: Pediatrics Date: 1995-01 Impact factor: 7.124
Authors: Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang Journal: Surv Ophthalmol Date: 2018-04-19 Impact factor: 6.048